Open Access

Femtosecond‑LASIK outcomes using the VisuMax®‑MEL® 80 platform for hyperopia and hyperopic astigmatism refractive surgery

  • Authors:
    • Bogdana Tăbăcaru
    • Horia Tudor Stanca
    • Ruxandra Angela Pîrvulescu
    • Simona Stanca
    • Ciprian Danielescu
    • Mihnea Munteanu
    • Cosmin Roșca
    • Adrian Cosmin Teodoru
  • View Affiliations

  • Published online on: January 26, 2021     https://doi.org/10.3892/etm.2021.9719
  • Article Number: 288
  • Copyright: © Tăbăcaru et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study evaluated the efficacy, the safety and the predictability of the Femtosecond laser-assisted in situ keratomileusis (Femto‑LASIK) procedure for hyperopia and hyperopic astigmatism. We retrospectively analyzed the postoperative 12‑month evolution of 593 eyes with hyperopia and hyperopic astigmatism that underwent Femto‑LASIK treatment. The procedure was predictable and effective. No eye lost 2 lines of corrected distance visual acuity (CDVA), demonstrating a safety profile of the procedure. Nine percent of the eyes gained at least one line of CDVA. The accuracy of the spherical equivalent after 12 months was 74% within ±1.0 diopter (D) of emmetropia. The refractive outcomes were stable during the follow‑up period. There were no significant complications during the procedure. Femto‑LASIK using the VisuMax®‑MEL® 80 platform was demonstrated to be a suitable option to correct selected cases of hyperopia and hyperopic astigmatism. A longer follow‑up period is required to better assess the refractive results and to detect any further regression.
View Figures
View References

Related Articles

Journal Cover

March-2021
Volume 21 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tăbăcaru B, Stanca H, Pîrvulescu R, Stanca S, Danielescu C, Munteanu M, Roșca C and Teodoru A: Femtosecond‑LASIK outcomes using the VisuMax<sup>®</sup>‑MEL<sup>®</sup> 80 platform for hyperopia and hyperopic astigmatism refractive surgery. Exp Ther Med 21: 288, 2021
APA
Tăbăcaru, B., Stanca, H., Pîrvulescu, R., Stanca, S., Danielescu, C., Munteanu, M. ... Teodoru, A. (2021). Femtosecond‑LASIK outcomes using the VisuMax<sup>®</sup>‑MEL<sup>®</sup> 80 platform for hyperopia and hyperopic astigmatism refractive surgery. Experimental and Therapeutic Medicine, 21, 288. https://doi.org/10.3892/etm.2021.9719
MLA
Tăbăcaru, B., Stanca, H., Pîrvulescu, R., Stanca, S., Danielescu, C., Munteanu, M., Roșca, C., Teodoru, A."Femtosecond‑LASIK outcomes using the VisuMax<sup>®</sup>‑MEL<sup>®</sup> 80 platform for hyperopia and hyperopic astigmatism refractive surgery". Experimental and Therapeutic Medicine 21.3 (2021): 288.
Chicago
Tăbăcaru, B., Stanca, H., Pîrvulescu, R., Stanca, S., Danielescu, C., Munteanu, M., Roșca, C., Teodoru, A."Femtosecond‑LASIK outcomes using the VisuMax<sup>®</sup>‑MEL<sup>®</sup> 80 platform for hyperopia and hyperopic astigmatism refractive surgery". Experimental and Therapeutic Medicine 21, no. 3 (2021): 288. https://doi.org/10.3892/etm.2021.9719